Male contraception: Past, present and future

References

• Amarin Z O, Obeidat B R. Patency following vasectomy reversal. Temporal and immunological considerations. Saudi Medical Journal 2005; 26: 1208–1211
   PubMedGoogle Scholar
• Bagatell C J, Conn P M, Bremner W J. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men. Fertility and Sterility 1993; 60: 680–685
   PubMedGoogle Scholar
• Behre H M, Klein B, Steinmeyer E, McGregor G P, Voigt K, Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. Journal of Clinical Endocrinology and Metabolism 1992; 75: 393–398
   PubMed Web of Science ®Google Scholar
• Benoff S, Hurley I, Cooper G W, Mandel F S, Hershlag A, Scholl G M, et al. Fertilisation potential in vitro is correlated with head-specific mannose-ligand receptor expression, acrosome status and membrane cholesterol content. Human Reproduction 1993; 8: 2155–2166
   PubMed Web of Science ®Google Scholar
• Best K. Contraceptive update: Experimental male methods inhibit sperm. Network 1998; 18
   PubMedGoogle Scholar
• Bujan L, Mieusset R. Male contraception by hyperthermia. Contraceptive Fertilite Sexualite (Paris) 1995; 23: 611–614
   Google Scholar
• Finger W R. Withdrawal popular in some cultures. Contraceptive update. Network 1996; 17, 24: 15–16
   Google Scholar
• Gu Y Q, Wang X H, Xu D, Peng L, Cheng L F, Huang M K, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. Journal of Clinical Endocrinology and Metabolism 2003; 88: 562–568
   PubMed Web of Science ®Google Scholar
• Guha S K, Singh G, Anand S, Ansari S, Kumar S, Koul V. Phase I clinical trial of an injectable contraceptive for the male. Contraception 1993; 48: 367–375
   PubMed Web of Science ®Google Scholar
• Guha S K, Singh G, Ansari S, Kumar S, Srivastava A, Koul V, et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 1997; 56: 245–250
   PubMed Web of Science ®Google Scholar
• Guillebaud J. Contraception you question answered. 3rd ed. Churchill Livingstone, Edinburgh 2002
   Google Scholar
• Hall J C. X-ray crystallographic and affinity labeling analysis of the structure of rat epididymal N-acetyl-β-D-hexosaminidase: Insight into the catalytic mechanism. 1997, National Science Foundation award abstract, No. 9804595
   Google Scholar
• Henry J B, Derrick Fc J. Immunological effects of vasectomy. Journal of the American Medical Association 1973; 225: 642
   Google Scholar
• Herbst K L, Coviello A D, Page S, Amory J K, Anawalt B D, Bremner W J. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. Journal of Clinical Endocrinology and Metabolism 2004; 89: 5959–5965
   PubMed Web of Science ®Google Scholar
• Hershlag A, Cooper G W, Benoff S. Pregnancy following discontinuation of a calcium channel blocker in the male partner. Human Reproduction 1995; 10: 599–606
   PubMedGoogle Scholar
• http://reliance3.securesites.net/bettersex/anal.shtml
   Google Scholar
• Jorgensen N, Giwercman A, Hansen S W, Skakkebaek N E. Testicular cancer after vasectomy: origin from carcinoma in situ of the testis. European Journal of Cancer 1993; 29A: 1062–1064
   PubMedGoogle Scholar
• Kapor-stanulovic N, Beric B M. The Greek Orthodox Church and position regarding birth control. Contraception Fertilite Sexualite (Paris) 1983; 11: 1053–1055
   PubMedGoogle Scholar
• Kirby D, Utz W J, Parks P J. An implantable ligation device that achieves male sterilisation without cutting the vas deferens. Urology 2006; 67: 807–811
   PubMedGoogle Scholar
• Koul V, Srivastava A, Guha S K. Reversibility with sodium bicarbonate of styrene maleic anhydride, an intravasal injectable contraceptive, in male rats. Contraception 1998; 58: 227–231
   PubMedGoogle Scholar
• Li S Q, Goldstein M, Zhu J, Huber D. The no-scalpel vasectomy. Journal of Urology 1991; 145: 341–344
   PubMed Web of Science ®Google Scholar
• Lohiya N K, Manivannan B, Mishra P K. Ultrastructural changes in the spermatozoa of langur monkeys Presbytis entellus entellus after vas occlusion with styrene maleic anhydride. Contraception 1998; 57: 125–132
   PubMedGoogle Scholar
• Lohiya N K, Manivannan B, Mishra P K. Repeated vas occlusion and non-invasive reversal with styrene maleic anhydride for male contraception in langur monkeys. International Journal of Andrology 2000; 23: 36–42
   PubMedGoogle Scholar
• Merggiola C, Farley T, Mbizvo M T. A review of androgen-progestin regimens for male contraception. Journal of Andrology 2003; 24: 466–483
   PubMedGoogle Scholar
• Mieusset R, Bujan L, Mansat A, Pontonnier F, Grandjean H. Hyperthermia and human spermatogenesis: enhancement of the inhibitory effect obtained by ‘artificial cryptorchidism’. International Journal of Andrology 1987; 10: 571–580
   PubMedGoogle Scholar
• Mieusset R, Bujan L, Mansat A, Grandjean H, Pontonnier F. Heat induced inhibition of spermatogenesis in man. Advances in experimental medicine and biology 1991; 286: 233–237
   PubMedGoogle Scholar
• Mieusset R, Bujan L. The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. International Journals of Andrology 1994; 17: 186–191
   PubMedGoogle Scholar
• Mishra P K, Manivannan B, Pathak N, Sriram S, Bhande S S, Panneerdoss S, et al. Status of spermatogenesis and sperm parameters in langur monkeys following long-term vas occlusion with styrene maleic anhydride. International Journal of Andrology 2003; 24: 501
   Google Scholar
• Moudgal N R, Jeyakumar M, Krishnamurthy H N, Sridhar S, Krishnamurthy H, Martin F. Development of male contraception vaccine – a perspective. Human Reproductive Update 1997; 3: 335–346
   PubMed Web of Science ®Google Scholar
• O'rand M G, Widgren E E, Sivashanmugam P, Richardson R T, Hall S H, French F S, et al. Reversible immunocontraception in male monkeys immunized with Eppin. Science 2004; 306: 1189–1190
   PubMedGoogle Scholar
• Qian S Z. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 1987; 36: 335–345
   PubMed Web of Science ®Google Scholar
• Qian S Z, Hu Y Z, Tong J S. Studies on the effect of Tripterygium wilfordii on the reproduction of men. Chinese Journal of Andrology 1989; 3: 129–132
   Google Scholar
• Rajfer J, Bennett C J. Vasectomy. Urologic Clinics of North America 1988; 15: 631–634
   PubMedGoogle Scholar
• Sharma V, Sharma A. Family planning practices among tribals of South Rajasthan, India. Journal of Research and Education in Indian Medicine 1991; 10: 5–9
   PubMedGoogle Scholar
• Sharma U, Chaudhury K, Jagannathan N R, Guha S K. A proton NMR study of the effect of a new intravasal injectable male contraceptive RISUG on seminal plasma metabolites. Reproduction 2001; 122: 431–436
   PubMedGoogle Scholar
• Sokal D, McMullen S, Gates D, Dominik R. A comparative study of the no scalpel and standard incision approaches to vasectomy in 5 countries. The Male Sterilization Investigator Team. Journal of Urology 1999; 162: 1621–1625
   PubMed Web of Science ®Google Scholar
• Suganuma R, Walden C M, Butters T D, Platt F M, Dwek R A, Yanagimachi R, et al. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biology of Reproduction 2005; 72: 805–813
   PubMedGoogle Scholar
• Swerdloff R S, Bagatell C J, Wang C, Anawalt B D, Berman N, Steiner B, et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3527–3533
   PubMed Web of Science ®Google Scholar
• Thau R. Anti-LHRH and anti-pituitary gonadotropin vaccines: their development and clinical applications. Scandinavian Journal of Immunology Supplement 1992; 11: 127–130
   PubMedGoogle Scholar
• Turner L, Conway A J, Jimenez M, Liu P Y, Forbes E, McLachlan R I, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. Journal of Clinical Endocrinology and Metabolism 2003; 88: 4659–4667
   PubMed Web of Science ®Google Scholar
• van der Spoel A C, Jeyakumar M, Butters T D, Charlton H M, Moore H D, Dwek R A, et al. Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 17173–17178
   PubMedGoogle Scholar
• Vasclip clinical study results, . Available at: http://www.vasclip.com/Webpage.asp?MID=818885
   Google Scholar
• Vogelsong K. Male contraception. WHO, Geneva 2005, WHO/World Bank Special Programme of Research Development and Research Training in Human Reproduction
   Google Scholar
• Waites G MH, Wang C, Griffin P D. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. International Journal of Andrology 1998; 21: 8–12
   PubMedGoogle Scholar
• WHO Task Force on methods for the regulation of male fertility. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertility and Sterility 1993; 60: 1062–1068
   PubMedGoogle Scholar
• WHO Task Force on methods for the regulations of male fertility. Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. International Journal of Andrology 1995; 18: 157–165
   PubMedGoogle Scholar